Skip to main content
PERCHERON THERAPEUTICS LIMITED logo

PERCHERON THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PER ISIN · AU0000317281 LEI · 984500FF63A961E0K787 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,206 across all filing types
Latest filing 2022-01-27 Capital/Financing Update
Country AU Australia
Listing ASX PER

About PERCHERON THERAPEUTICS LIMITED

https://percherontx.com

Percheron Therapeutics Limited is a clinical-stage company focused on the development of novel antisense pharmaceuticals for rare diseases. The company's lead program, ATL1102, is an antisense oligonucleotide targeting the CD49d receptor, a subunit of the VLA-4 integrin. This therapeutic candidate is primarily being developed for the treatment of Duchenne muscular dystrophy (DMD), where it aims to reduce inflammation and muscle damage by modulating the immune system's response. Formerly known as Antisense Therapeutics, the firm utilizes its proprietary antisense technology platform to create targeted therapies that inhibit the production of proteins associated with disease progression. The company's research and development efforts are centered on addressing significant unmet medical needs through precision genetic medicine.

Recent filings

Filing Released Lang Actions
Cleansing Notice 1 page 196.7KB
Capital/Financing Update Classification · 95% confidence The document is a notice under section 708A(5) of the Corporations Act regarding the issue of ordinary shares without disclosure under Part 6D.2 of the Corporations Act. It provides details about the share issue such as number of shares, issue price, and compliance statements. The document is short (1296 characters) and is a regulatory compliance notice related to capital raising but does not contain financial statements or detailed financial data. It is not an announcement of a report publication but a formal regulatory notice. This fits best under Capital/Financing Update (CAP) as it relates to company fundraising and capital structure changes.
2022-01-27 English
Quarterly Report and Appendix 4C 9 pages 298.7KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Quarterly Activities Report & Appendix 4C' and provides detailed updates on the company's activities for the quarter ended 31 December 2021. It includes operational updates, regulatory progress, clinical trial information, capital raising details, board appointments, AGM results, intellectual property updates, and cash flow statements. The presence of Appendix 4C, which is a quarterly cash flow report required by the ASX Listing Rules, confirms this is a quarterly report. The document contains substantive financial data and analysis for the quarter, not just an announcement or summary. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q2 2022
2022-01-26 English
Proposed issue of securities - ANP 5 pages 27.3KB
Capital/Financing Update Classification · 100% confidence The document is an announcement regarding a proposed issue of securities by Antisense Therapeutics Limited. It details the number of securities to be issued, the type of securities, the issue date, and compliance with ASX listing rules. There is no financial performance data, management discussion, or detailed financial statements. The document is focused on informing about a capital raising or share issuance event. This fits the definition of a Capital/Financing Update (CAP) filing, which covers updates on company fundraising or capital structure changes.
2022-01-26 English
Application for quotation of securities - ANP 6 pages 27.7KB
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Application for quotation of +securities' and details the application to list new securities on the ASX. It includes information about the entity, the securities to be quoted, issue dates, and distribution schedules. It references a previous Appendix 3B announcement related to the securities issuance. The content focuses on the quotation and listing of securities rather than financial results, management changes, or other report types. This fits the category of Share Issue/Capital Change (SHA), which covers announcements regarding new share issues or capital changes. The document length is about 5,399 characters, containing substantive details about the securities issuance and quotation application, not merely a brief announcement or a report publication notice.
2021-12-23 English
Cleansing Notice 1 page 178.8KB
Capital/Financing Update Classification · 95% confidence The document is a notice under Section 708A(5) of the Corporations Act regarding the issue of ordinary shares without disclosure under Part 6D.2 of the Corporations Act. It provides details about the share issue such as number issued, issue price, and compliance statements. The document is short (1298 characters) and is an announcement of a capital raising event without detailed financial statements or analysis. This fits the definition of a Capital/Financing Update (CAP) rather than a full financial report or regulatory filing. Therefore, the appropriate classification is CAP.
2021-12-23 English
Proposed issue of securities - ANP 5 pages 27.3KB
Capital/Financing Update Classification · 100% confidence The document is an announcement from Antisense Therapeutics Limited regarding a proposed issue of securities, specifically a placement or other type of issue of ordinary fully paid shares. It details the number of securities to be issued, the issue date, conditions, and compliance with ASX listing rules. There is no financial report, earnings data, or management discussion. The content focuses on capital raising activities and share issuance. Therefore, this fits the category of Capital/Financing Update (CAP). The document length and detail confirm it is not a brief notice but a full announcement of a capital issue.
2021-12-22 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.